$54,70
+$0,62(+1,14%)
*Data last updated: 2026-05-10 21:22 (UTC+8)
As of 2026-05-10 21:22, BioMarin Pharmaceutical Inc (BMRN) is priced at $54,70, with a total market cap of $10,39B, a P/E ratio of 32,66, and a dividend yield of 0,00%. Today, the stock price fluctuated between $53,21 and $55,21. The current price is 2,80% above the day's low and 0,92% below the day's high, with a trading volume of 1,97M. Over the past 52 weeks, BMRN has traded between $52,00 to $57,44, and the current price is -4,77% away from the 52-week high.
BMRN Key Stats
Yesterday's Close$54,12
Market Cap$10,39B
Volume1,97M
P/E Ratio32,66
Dividend Yield (TTM)0,00%
Diluted EPS (TTM)1,39
Net Income (FY)$348,90M
Revenue (FY)$3,22B
Earnings Date2026-08-03
EPS Estimate0,97
Revenue Estimate$914,64M
Shares Outstanding192,10M
Beta (1Y)0.229
About BMRN
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.
SectorHealthcare
IndustryBiotechnology
CEOAlexander Hardy
HeadquartersSan Rafael,CA,US
Official Websitehttps://www.biomarin.com
Employees (FY)3,22K
Average Revenue (1Y)$1,00M
Net Income per Employee$108,32K
BioMarin Pharmaceutical Inc (BMRN) FAQ
What's the stock price of BioMarin Pharmaceutical Inc (BMRN) today?
x
BioMarin Pharmaceutical Inc (BMRN) is currently trading at $54,70, with a 24h change of +1,14%. The 52-week trading range is $52,00–$57,44.
What are the 52-week high and low prices for BioMarin Pharmaceutical Inc (BMRN)?
x
What is the price-to-earnings (P/E) ratio of BioMarin Pharmaceutical Inc (BMRN)? What does it indicate?
x
What is the market cap of BioMarin Pharmaceutical Inc (BMRN)?
x
What is the most recent quarterly earnings per share (EPS) for BioMarin Pharmaceutical Inc (BMRN)?
x
Should you buy or sell BioMarin Pharmaceutical Inc (BMRN) now?
x
What factors can affect the stock price of BioMarin Pharmaceutical Inc (BMRN)?
x
How to buy BioMarin Pharmaceutical Inc (BMRN) stock?
x
Risk Warning
The stock market involves a high level of risk and price volatility. The value of your investment may increase or decrease, and you may not recover the full amount invested. Past performance is not a reliable indicator of future results. Before making any investment decisions, you should carefully assess your investment experience, financial situation, investment objectives, and risk tolerance, and conduct your own research. Where appropriate, consult an independent financial adviser.
Disclaimer
The content on this page is provided for informational purposes only and does not constitute investment advice, financial advice, or trading recommendations. Gate shall not be held liable for any loss or damage resulting from such financial decisions. Further, take note that Gate may not be able to provide full service in certain markets and jurisdictions, including but not limited to the United States of America, Canada, Iran, and Cuba. For more information on Restricted Locations, please refer to the User Agreement.
